Determining the thrombophilic risk profile, in particular PAI-1 675 4G/5G gene polymorphism and hyperhomocysteinemia of patients with CVST at the time of the acute event may allow for the selection of patients who will need follow up after hospital discharge. The gene discussed is SERPINE1; the disease is hyperhomocysteinemia.